Ernexa Therapeutics Inc. Proceeds from Sale of Productive Assets
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Sale of Productive Assets of $2.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2021-03-11
- Ernexa Therapeutics Inc. proceeds from sale of productive assets for fiscal 2020 was $2.00M.
| Period end | Proceeds from Sale of Productive Assets 12 month |
|---|---|
| 2020-12-31 | $2.00M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |